Clinical effects of metformin in patients with nonobese type 2 diabetes

Kazuhiro Hosokawa, Shu Meguro, Osamu Funae, Chisato Murata, Kiyoe Katou, Atsuko Mokubo, Yoshihiko Suzuki, Sonoko Anazawa, Yosihito Atsumi, Kempei Matsuoka

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Metformin is indicated for obese insulin-resistant type 2 diabetic patients but also acts clinically in nonobese patients. We retrospectively studied 275 patients-172 men and 103 women undrergoing 1-year metformin monotherapy as outpatient at Saiseikai Central Hospital, Tokyo. Based on BMI, we divided them into Group 1 with a BMI of 22 or less, Group 2 with 22.1-24.9, and Group 3 with 25 and over. By group, baseline age was 60.1±9.8 years old for 1, 59.8±8.6 for 2, and 55.8±11.9 for 3. Diabetes duration was 13.0±7.2 years for Group 1, 11.1±7.3 for Group 2, and 8.7 ±6.3 for Group 3. Group 1 baseline HbA1c was 8.07±0.71%, 8.15±0.96% for Group 2, and 8.16±1.28% for Group 3. Six months after metformin monotreatment alone, HbA1c had decreased by -0.79±0.88% in Group 1, -0.81±1.0% in Group 2, and -0.73±1.06 % in Group 3, with no significant difference. Patient age Group 3 overall was somewhat younger and diabetes duration shorter, but the HbA1c reduction from baseline to six months was similar in all groups. In summary, the metformin effect in nonobese patients was equally effective as in obese patients.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalJournal of the Japan Diabetes Society
Volume52
Issue number1
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

Metformin
Type 2 Diabetes Mellitus
Tokyo
Outpatients
Age Groups
Insulin

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Hosokawa, K., Meguro, S., Funae, O., Murata, C., Katou, K., Mokubo, A., ... Matsuoka, K. (2009). Clinical effects of metformin in patients with nonobese type 2 diabetes. Journal of the Japan Diabetes Society, 52(1), 1-6.

Clinical effects of metformin in patients with nonobese type 2 diabetes. / Hosokawa, Kazuhiro; Meguro, Shu; Funae, Osamu; Murata, Chisato; Katou, Kiyoe; Mokubo, Atsuko; Suzuki, Yoshihiko; Anazawa, Sonoko; Atsumi, Yosihito; Matsuoka, Kempei.

In: Journal of the Japan Diabetes Society, Vol. 52, No. 1, 2009, p. 1-6.

Research output: Contribution to journalArticle

Hosokawa, K, Meguro, S, Funae, O, Murata, C, Katou, K, Mokubo, A, Suzuki, Y, Anazawa, S, Atsumi, Y & Matsuoka, K 2009, 'Clinical effects of metformin in patients with nonobese type 2 diabetes', Journal of the Japan Diabetes Society, vol. 52, no. 1, pp. 1-6.
Hosokawa, Kazuhiro ; Meguro, Shu ; Funae, Osamu ; Murata, Chisato ; Katou, Kiyoe ; Mokubo, Atsuko ; Suzuki, Yoshihiko ; Anazawa, Sonoko ; Atsumi, Yosihito ; Matsuoka, Kempei. / Clinical effects of metformin in patients with nonobese type 2 diabetes. In: Journal of the Japan Diabetes Society. 2009 ; Vol. 52, No. 1. pp. 1-6.
@article{f8ee46ec430e4ab19b2b045d91641485,
title = "Clinical effects of metformin in patients with nonobese type 2 diabetes",
abstract = "Metformin is indicated for obese insulin-resistant type 2 diabetic patients but also acts clinically in nonobese patients. We retrospectively studied 275 patients-172 men and 103 women undrergoing 1-year metformin monotherapy as outpatient at Saiseikai Central Hospital, Tokyo. Based on BMI, we divided them into Group 1 with a BMI of 22 or less, Group 2 with 22.1-24.9, and Group 3 with 25 and over. By group, baseline age was 60.1±9.8 years old for 1, 59.8±8.6 for 2, and 55.8±11.9 for 3. Diabetes duration was 13.0±7.2 years for Group 1, 11.1±7.3 for Group 2, and 8.7 ±6.3 for Group 3. Group 1 baseline HbA1c was 8.07±0.71{\%}, 8.15±0.96{\%} for Group 2, and 8.16±1.28{\%} for Group 3. Six months after metformin monotreatment alone, HbA1c had decreased by -0.79±0.88{\%} in Group 1, -0.81±1.0{\%} in Group 2, and -0.73±1.06 {\%} in Group 3, with no significant difference. Patient age Group 3 overall was somewhat younger and diabetes duration shorter, but the HbA1c reduction from baseline to six months was similar in all groups. In summary, the metformin effect in nonobese patients was equally effective as in obese patients.",
author = "Kazuhiro Hosokawa and Shu Meguro and Osamu Funae and Chisato Murata and Kiyoe Katou and Atsuko Mokubo and Yoshihiko Suzuki and Sonoko Anazawa and Yosihito Atsumi and Kempei Matsuoka",
year = "2009",
language = "English",
volume = "52",
pages = "1--6",
journal = "Journal of the Japan Diabetes Society",
issn = "0021-437X",
publisher = "Japan Diabetes Society",
number = "1",

}

TY - JOUR

T1 - Clinical effects of metformin in patients with nonobese type 2 diabetes

AU - Hosokawa, Kazuhiro

AU - Meguro, Shu

AU - Funae, Osamu

AU - Murata, Chisato

AU - Katou, Kiyoe

AU - Mokubo, Atsuko

AU - Suzuki, Yoshihiko

AU - Anazawa, Sonoko

AU - Atsumi, Yosihito

AU - Matsuoka, Kempei

PY - 2009

Y1 - 2009

N2 - Metformin is indicated for obese insulin-resistant type 2 diabetic patients but also acts clinically in nonobese patients. We retrospectively studied 275 patients-172 men and 103 women undrergoing 1-year metformin monotherapy as outpatient at Saiseikai Central Hospital, Tokyo. Based on BMI, we divided them into Group 1 with a BMI of 22 or less, Group 2 with 22.1-24.9, and Group 3 with 25 and over. By group, baseline age was 60.1±9.8 years old for 1, 59.8±8.6 for 2, and 55.8±11.9 for 3. Diabetes duration was 13.0±7.2 years for Group 1, 11.1±7.3 for Group 2, and 8.7 ±6.3 for Group 3. Group 1 baseline HbA1c was 8.07±0.71%, 8.15±0.96% for Group 2, and 8.16±1.28% for Group 3. Six months after metformin monotreatment alone, HbA1c had decreased by -0.79±0.88% in Group 1, -0.81±1.0% in Group 2, and -0.73±1.06 % in Group 3, with no significant difference. Patient age Group 3 overall was somewhat younger and diabetes duration shorter, but the HbA1c reduction from baseline to six months was similar in all groups. In summary, the metformin effect in nonobese patients was equally effective as in obese patients.

AB - Metformin is indicated for obese insulin-resistant type 2 diabetic patients but also acts clinically in nonobese patients. We retrospectively studied 275 patients-172 men and 103 women undrergoing 1-year metformin monotherapy as outpatient at Saiseikai Central Hospital, Tokyo. Based on BMI, we divided them into Group 1 with a BMI of 22 or less, Group 2 with 22.1-24.9, and Group 3 with 25 and over. By group, baseline age was 60.1±9.8 years old for 1, 59.8±8.6 for 2, and 55.8±11.9 for 3. Diabetes duration was 13.0±7.2 years for Group 1, 11.1±7.3 for Group 2, and 8.7 ±6.3 for Group 3. Group 1 baseline HbA1c was 8.07±0.71%, 8.15±0.96% for Group 2, and 8.16±1.28% for Group 3. Six months after metformin monotreatment alone, HbA1c had decreased by -0.79±0.88% in Group 1, -0.81±1.0% in Group 2, and -0.73±1.06 % in Group 3, with no significant difference. Patient age Group 3 overall was somewhat younger and diabetes duration shorter, but the HbA1c reduction from baseline to six months was similar in all groups. In summary, the metformin effect in nonobese patients was equally effective as in obese patients.

UR - http://www.scopus.com/inward/record.url?scp=61749089270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61749089270&partnerID=8YFLogxK

M3 - Article

VL - 52

SP - 1

EP - 6

JO - Journal of the Japan Diabetes Society

JF - Journal of the Japan Diabetes Society

SN - 0021-437X

IS - 1

ER -